BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16882082)

  • 1. Advanced prostate cancer with extremely low prostate-specific antigen value at diagnosis: an example of high dose hook effect.
    Akamatsu S; Tsukazaki H; Inoue K; Nishio Y
    Int J Urol; 2006 Jul; 13(7):1025-7. PubMed ID: 16882082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
    Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
    Int J Urol; 2006 Mar; 13(3):303-4. PubMed ID: 16643633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prostatic cancer with cystic formation: a case report].
    Kubo M; Taguchi K; Fujisue H; Ihara H; Ikoma F
    Hinyokika Kiyo; 1998 Dec; 44(12):883-6. PubMed ID: 10028435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A case of prostate cancer with cyst formation].
    Ishida K; Kubota Y; Takada T; Yamada T; Nakano M; Takahashi Y; Ishihara S; Deguchi T
    Hinyokika Kiyo; 2003 Apr; 49(4):235-7. PubMed ID: 12784721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Marked effectiveness of the LH-RH analogue in a case of prostate cancer with large lymph node metastasis].
    Takezawa Y; Ohtake N; Nakano K; Uchida T; Okamura K; Yamanaka H
    Hinyokika Kiyo; 1994 Aug; 40(8):721-4. PubMed ID: 7942372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A case of ductal carcinoma of the prostate after transurethral resection of prostate].
    Izumi K; Kanno H; Umemoto S; Hasumi H; Osada Y; Ota J; Tsuchiya F; Ogino I; Harada M
    Hinyokika Kiyo; 2007 May; 53(5):315-8. PubMed ID: 17561717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.
    Gittelman M; Pommerville PJ; Persson BE; Jensen JK; Olesen TK;
    J Urol; 2008 Nov; 180(5):1986-92. PubMed ID: 18801505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A case of prostate cancer that developed following transurethral resection of the prostate: diagnostic efficiency of diffusion-weighted images on magnetic resonance imaging].
    Ohzeki T; Mori Y; Katoh Y; Iguchi M; Yamasaki M
    Hinyokika Kiyo; 2010 May; 56(5):277-80. PubMed ID: 20519927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
    Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
    Int J Urol; 2006 Jan; 13(1):87-8. PubMed ID: 16448441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prostatic cancer with cystic formation: a case report].
    Takayama H; Arai Y; Meguro N; Maeda O; Saiki S; Kinouchi T; Kuroda M; Usami M; Kotake T
    Hinyokika Kiyo; 1996 Dec; 42(12):977-80. PubMed ID: 9013236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
    Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of prostate cancer presenting as a symptomatic abdominal mass.
    Nagayoshi J; Kawakami T; Maruyama Y; Cho M
    Hinyokika Kiyo; 1997 Oct; 43(10):751-4. PubMed ID: 9395915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prostatic cancer in a young adult: a report of 2 cases].
    Sasaki H; Miki J; Hasegawa T; Hasegawa N; Ikemoto I; Ohishi Y
    Hinyokika Kiyo; 2004 Jan; 50(1):57-9. PubMed ID: 15032019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure to achieve a PSA level Mitchell DM; McAleese J; Park RM; Stewart DP; Stranex S; Eakin RL; Houston RF; O'Sullivan JM
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1467-71. PubMed ID: 17689886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combined small-cell carcinoma/adenocarcinoma of prostate: report of two cases].
    Sakuma T; Yoshida T; Ohashi H; Nishimura K; Kawano K
    Hinyokika Kiyo; 2007 Jul; 53(7):489-92. PubMed ID: 17702184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of prostate-specific antigen and prostate-specific antigen density in detection of prostate cancer in an Iranian population of men.
    Ghafoori M; Varedi P; Hosseini SJ; Asgari M; Shakiba M
    Urol J; 2009; 6(3):182-8. PubMed ID: 19711272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.